<DOC>
	<DOCNO>NCT02071004</DOCNO>
	<brief_summary>This phase 1 , open label , single dose study , 5 day aspirin treatment , healthy male female subject . It hypothesize co-administering DS-1040b aspirin steady state safe well tolerate healthy male female subject .</brief_summary>
	<brief_title>DS1040b/Aspirin Drug/Drug Interaction Study</brief_title>
	<detailed_description />
	<mesh_term>Aspirin</mesh_term>
	<criteria>Healthy male female subject , age 18 45 year . A body mass index ( BMI , Quetlet index ) range 18.0 30.0 kg/m2 , weigh 50 100 kg screening . Male subject agree contraception ( condom spermicide ) addition female partner ( childbearing potential ) use another form contraception ( e.g. , intrauterine device , diaphragm spermicide , oral contraceptive , injectable , sub dermal hormonal implant ) first dose 16 week follow last dose administration . Also , male subject must donate sperm study period four month . All woman must negative serum pregnancy test screen negative urine pregnancy test admission ( Day 1 ) . Women must nonchildbearing potential either : Surgically sterile ( i.e. , bilateral tubal ligation removal ovary and/or uterus least 6 month prior dose ) naturally postmenopausal ( spontaneous cessation menses ) least 24 consecutive month prior dose , follicle stimulate hormone ( FSH ) level screen ≥ 40 mIU/mL . Sufficient intelligence understand nature trial hazard participate . Ability communicate satisfactorily Investigator participate , comply requirement , entire trial . Willingness give write consent participate reading ICF , opportunity discuss trial Investigator delegate . Willingness give write consent data enter The Overvolunteering Prevention Scheme . Willing abstain grapefruit/grapefruit juice Seville oranges 7 day first dose throughout study . Willing refrain consume food beverage contain caffeine/xanthine start 24 hour prior checkin Day 1 . Clinically relevant abnormal history , include cardiovascular , haematologic , pulmonary , hepatic , renal , gastrointestinal , connective tissue disease , uncontrolled endocrine/metabolic , oncologic ( within last 5 year ) , neurologic ( include previous transient ischemic attack stroke ) , psychiatric disease , physical finding , ECG , laboratory value pretrial screening assessment could interfere objective trial safety volunteer . History serious reaction medicine . History major bleeding , stomach ulcer , Raynaud 's disease , major trauma , major surgical procedure type within 6 month dose . History minor bleeding episode epistaxis , rectal bleeding ( spots blood toilet paper ) , gingival bleeding within 3 month study treatment . Familial document suspect coagulopathy haemoglobinopathy . Females history dysfunctional uterine bleeding , include history menorrhagia , metrorrhagia , polymenorrhea . History operation ( e.g . stomach bypass ) , condition could affect body handle absorb medicine . History gastrooesophageal reflux disease . Females breastfeed . Positive urine faecal occult blood test screen admission ( Day 1 day 1 ) . Bleeding time &gt; 9.5 minute screen ) . aPTT , PT , INR , platelet count outside limit normal clinical laboratory 's reference range screening . Estimated glomerular filtration rate ( eGFR ) &lt; 60 mL/min/1.73m2 ( base Modification Diet Renal Disease [ MDRD ] equation ) . Positive test hepatitis B , hepatitis C , HIV1 &amp; HIV2 . QTcF interval duration &gt; 430 msec male 450 msec female , obtain average 3 ECG measurement triplicate screen ECGs . Abnormal waveform morphology ECGs screening admission would preclude accurate measurement QT interval duration . Physical trauma , dental extraction , surgery , significant illness within 4 week first dose . History presence keloid , hyperpigmentation , adverse reaction skin injury surgery . Use prescribed nonprescribed ( overthecounter [ OTC ] ) systemic medication ( include anticoagulant antiplatelet medication ) , topical medication , herbal supplement within 14 day first dose ( exclude paracetamol ≤ 2 g/day ) . St. John 's Wort ( hypericin ) must take least 30 day first dose . Donated lose &gt; 400 mL blood plasma 3 month first dose Day 1 . Donation blood , plasma , platelet , blood component 3 month trial , unwilling abstain study 3 month receipt trial medication . Participated clinical study involve administration investigational drug , market drug within 90 day administration first dose . Male subject consume 21 unit alcohol per week female subject consume 14 unit alcohol per week ( 1 unit alcohol equal 1/2 pint beer , glass wine , 1 measure spirit ) subject significant history alcoholism drug/chemical abuse within last 2 year . Use tobacco product nicotinecontaining product within 3 month first dose . Positive result test drug abuse , carbon monoxide , alcohol screen admission . Possibility volunteer cooperate requirement protocol . Objection General Practitioner ( GP ) volunteer enter trial . Known aspirin allergy intolerance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>acute ischemic stroke</keyword>
</DOC>